The Cancer Moonshot: Fueling Growth and Innovation in Hospital Research

The Cancer Moonshot boosts hospital research by funding clinical trials, driving innovation, and advancing cancer care while addressing challenges like inclusivity and compliance.

• Read more about The Cancer Moonshot: Fueling Growth and Innovation in Hospital Research

Three Critical Steps to Prepare for DSCSA Compliance

This article outlines three essential steps for pharmacies to prepare for full DSCSA compliance: verifying global identifiers, training staff on serialized product verification, and assessing eligibility for waivers or exemptions. By taking these proactive measures, pharmacies can ensure seamless data sharing, prevent inventory delays, and maintain compliance as new requirements take effect.

• Read more about Three Critical Steps to Prepare for DSCSA Compliance

Why Serialized Data Shouldn’t Wait Until Full Enforcement

Early adoption of serialized data tracking is crucial for healthcare facilities to combat counterfeit drugs and enhance supply chain security ahead of full DSCSA enforcement. Despite current data gaps and compliance delays among manufacturers, starting now ensures safer, more efficient operations, benefiting hospitals, pharmacies, and manufacturers.

• Read more about Why Serialized Data Shouldn’t Wait Until Full Enforcement

The Critical Role of Specialty Pharmacies in Breast Cancer Care

Specialty pharmacies are essential in breast cancer care, offering life-saving medications and support that go beyond dispensing drugs. They provide counseling, monitor patient progress, and navigate insurance complexities to ensure women have access to critical treatments. However, challenges like inadequate reimbursement and high costs hinder their ability to deliver these services. Streamlining the system and reducing barriers can help specialty pharmacies continue their vital role in saving lives.

• Read more about The Critical Role of Specialty Pharmacies in Breast Cancer Care

Join Us in Advancing Safe Medication Disposal on National Prescription Drug Take-Back Day

As National Prescription Drug Take-Back Day approaches on October 26, Inmar highlights the importance of safe medication disposal to prevent misuse. Since 2017, Inmar’s Consumer Drug Take-Back Program has collected over 3 million pounds of unused medications. With more than 6,400 collection kiosks nationwide, Inmar continues to provide convenient disposal options, helping reduce the risk of prescription drug misuse and protect communities. Businesses and pharmacies are encouraged to support responsible disposal efforts for a safer, healthier environment.

• Read more about Join Us in Advancing Safe Medication Disposal on National Prescription Drug Take-Back Day

How DSCSA Boosts Crisis Resilience: Strengthening Pharmacies and Hospitals

This article explores how the Drug Supply Chain Security Act (DSCSA) enhances crisis resilience for pharmacies and hospitals by improving product traceability. It highlights the critical role DSCSA plays during supply chain disruptions caused by natural disasters, such as Hurricane Helene, enabling healthcare providers to maintain access to essential medications and ensure patient safety. By leveraging DSCSA’s serialized data and chain of custody insights, pharmacies and hospitals can proactively address challenges and strengthen their operational preparedness.

• Read more about How DSCSA Boosts Crisis Resilience: Strengthening Pharmacies and Hospitals

FTC versus the PBMs: The Battle to Lower Insulin Prices and Reform PBMs

The FTC has filed a lawsuit against major pharmacy benefit managers (PBMs), accusing them of inflating insulin prices through anticompetitive practices that harm patients. This legal battle could lead to significant PBM reforms, ensuring fair pricing for essential medications like insulin. The lawsuit highlights the rising cost of insulin, forcing many patients to ration their medication or go without due to high out-of-pocket expenses. If successful, the case could set a new precedent in holding PBMs accountable and improving access to affordable medications for millions of patients.

• Read more about FTC versus the PBMs: The Battle to Lower Insulin Prices and Reform PBMs

Delaying DSCSA Enforcement: The Right Decision for all the Right Reasons

Brian Nightengale, EVP and President of Healthcare at Inmar Intelligence, discusses the FDA’s recent decision to delay DSCSA enforcement. The delay offers pharmaceutical supply chain partners more time to fully achieve compliance and address operational challenges related to electronic interoperability and product traceability. Nightengale praises the decision as a thoughtful and proactive move to prevent disruptions in medication distribution while maintaining focus on patient safety and the integrity of the supply chain. He urges industry stakeholders to continue prioritizing efforts toward full DSCSA compliance.

• Read more about Delaying DSCSA Enforcement: The Right Decision for all the Right Reasons

You Previously Qualified for a Small Dispenser DSCSA Exemption. Now What?

This article, originally published in Pharmacy Times, explores the DSCSA exemption for small dispensers and outlines their current and future regulatory obligations. It highlights the importance of staying compliant with key DSCSA requirements, including verifying trading partner licenses, maintaining product tracing documentation, and preparing for full electronic interoperability by the 2026 deadline.

• Read more about You Previously Qualified for a Small Dispenser DSCSA Exemption. Now What?